- $2.07bn
- $1.94bn
- $219.86m
- 96
- 11
- 78
- 65
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 39.63 | ||
| PEG Ratio (f) | 3.25 | ||
| EPS Growth (f) | 13.87% | ||
| Dividend Yield (f) | 0.73% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.14 | ||
| Price to Tang. Book | 8.79 | ||
| Price to Free Cashflow | 55.7 | ||
| Price to Sales | 9.41 | ||
| EV to EBITDA | 31.33 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.03% | ||
| Return on Equity | 13.87% | ||
| Operating Margin | 23.77% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 129.37 | 154.42 | 161.65 | 193.48 | 219.86 | 239.26 | 259.54 | 13.4% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +15.42 | +23.03 | -17.32 | +31.19 | +42.25 | +15.71 | +10.46 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold primarily in the United States, Europe, Canada, and Asia Pacific.
Directors
- George LeMaitre CHM (56)
- David Roberts PRE (56)
- Joseph Pellegrino CFO (56)
- Laurie Churchill SVP (50)
- Andrew Hodgkinson SVP (45)
- Trent Kamke SVP (50)
- Stephane Maier SVP (45)
- Giovannella Deiure VPR (52)
- Chance Kriesel VPR (48)
- Kimberly Cieslak VPR (48)
- Roli Kumar-Choudhury VPR (42)
- Jonathan Ngau VPR (47)
- Jacob Petersen VPR (44)
- James Russell VPR (45)
- Xiang Zhang VPR (48)
- Ryan Connelly VRD (43)
- Helen Goulding DSL (60)
- Ina Leininger DSL (38)
- Daniel Mumford DHR (39)
- Christopher Minnett OTH (49)
- Lawrence Jasinski IND (63)
- John O'Connor IND (73)
- Bridget Ross IND (56)
- John Roush IND (56)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 15th, 1998
- Public Since
- October 19th, 2006
- No. of Shareholders
- 155
- No. of Employees
- 651
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 22,594,362
- Address
- 63 2nd Ave, BURLINGTON, 01803-4413
- Web
- https://www.lemaitre.com/
- Phone
- +1 7812212266
- Auditors
- Grant Thornton LLP
Upcoming Events for LMAT
Q1 2025 LeMaitre Vascular Inc Earnings Call
LeMaitre Vascular Inc Annual Shareholders Meeting
Q2 2025 LeMaitre Vascular Inc Earnings Release
Similar to LMAT
908 Devices
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
Anteris Technologies Global
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Beta Bionics
NASDAQ Global Market
FAQ
What is the Lemaitre Vascular share price?
As of Today at 21:44 UTC, shares in Lemaitre Vascular are trading at $91.61. This share price information is delayed by 15 minutes.
How has the Lemaitre Vascular share price performed this year?
Shares in Lemaitre Vascular last closed at $91.61 and the price had moved by +45.44% over the past 365 days. In terms of relative price strength the Lemaitre Vascular share price has outperformed the S&P500 Index by +34.24% over the past year.
What are the analyst and broker recommendations for Lemaitre Vascular?
The overall consensus recommendation for Lemaitre Vascular is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Lemaitre Vascular dividend yield?
The Lemaitre Vascular dividend yield is 0.68% based on the trailing twelve month period.
Does Lemaitre Vascular pay a dividend?
Last year, Lemaitre Vascular paid a total dividend of $0.62, and it currently has a trailing dividend yield of 0.68%. We do not have any data on when Lemaitre Vascular is to next pay dividends.
When does Lemaitre Vascular next pay dividends?
We do not have data on when Lemaitre Vascular is to next pay dividends. The historic dividend yield on Lemaitre Vascular shares is currently 0.68%.
How do I buy Lemaitre Vascular shares?
To buy shares in Lemaitre Vascular you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Lemaitre Vascular?
As of the previous close price of $91.61, shares in Lemaitre Vascular had a market capitalisation of $2.07bn.
Where are Lemaitre Vascular shares listed?
Here are the trading details for Lemaitre Vascular:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: LMAT
What kind of share is Lemaitre Vascular?
Based on an overall assessment of its quality, value and momentum Lemaitre Vascular is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Lemaitre Vascular share price forecast for 2025?
The analyst consensus target price for shares in Lemaitre Vascular is $105.63. That is 15.3% above the last closing price of $91.61.
Analysts covering Lemaitre Vascular currently have a consensus Earnings Per Share (EPS) forecast of $2.24 for the next financial year.
Find out moreWhat is the trend in the Lemaitre Vascular share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lemaitre Vascular. Over the past six months, its share price has outperformed the S&P500 Index by +12.75%.
As of the last closing price of $91.61, shares in Lemaitre Vascular were trading +0.06% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Lemaitre Vascular PE Ratio?
The Lemaitre Vascular PE ratio based on its reported earnings over the past 12 months is 39.63. The shares last closed at $91.61.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Lemaitre Vascular?
Lemaitre Vascular's management team is headed by:
- George LeMaitre - CHM
- David Roberts - PRE
- Joseph Pellegrino - CFO
- Laurie Churchill - SVP
- Andrew Hodgkinson - SVP
- Trent Kamke - SVP
- Stephane Maier - SVP
- Giovannella Deiure - VPR
- Chance Kriesel - VPR
- Kimberly Cieslak - VPR
- Roli Kumar-Choudhury - VPR
- Jonathan Ngau - VPR
- Jacob Petersen - VPR
- James Russell - VPR
- Xiang Zhang - VPR
- Ryan Connelly - VRD
- Helen Goulding - DSL
- Ina Leininger - DSL
- Daniel Mumford - DHR
- Christopher Minnett - OTH
- Lawrence Jasinski - IND
- John O'Connor - IND
- Bridget Ross - IND
- John Roush - IND